Vaccí de Sanofi-GSK contra la COVID-19
| Dades clíniques | |
|---|---|
| Grup farmacològic | vaccí contra la COVID-19  |
El vaccí de Sanofi-GSK contra la COVID-19 també coneguda com VAT00002 és un vaccí contra la COVID-19, candidat, desenvolupat per Sanofi Pasteur i GSK.[1][2][3]
Referències[modifica]
- ↑ «Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older». United States National Library of Medicine.
- ↑ «Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)». United States National Library of Medicine.
- ↑ «Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.». Pan African Clinical Trials Registry.
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
